ReviewJournal of cancer research and clinical oncology2022
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.
Review in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- Pooled it
- SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Guideline
- Comments on "Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma".Korean journal of radiology · 2026Article
- Response to Comments on "Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma".Korean journal of radiology · 2026Article
- Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.Korean journal of radiology · 2025Article
- ESR Bridges: renal cell carcinoma-a multidisciplinary view.European radiology · 2025Article
- Review
- Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study).EJNMMI research · 2025Article
- Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma.The oncologist · 2025Review
- Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.Abdominal radiology (New York) · 2025Review
- Article
- PSMA PET/CT Incidental Detection of Tumor Thrombus From Unsuspected Renal Cell Carcinoma and Comparison with FDG PET/CT.Case reports in radiology · 2025Article
- Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Stereotactic ablative radiotherapy: a game-changer in primary renal cancer therapy.Translational andrology and urology · 2024Article
- Characterization ofCancers · 2024Article
- Article
- PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches.Biomedicines · 2023Article
- PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal masses detection is continually increasing worldwide, with Renal Cell Carcinoma (RCC) accounting for approximately 90% of all renal cancers and remaining one of the most aggressive urological malignancies. Despite improvements in cancer management, accurate diagnosis and treatment strategy of RCC by computed tomography (CT) and magnetic resonance imaging (MRI) are still challenging. Prostate-Specific Membrane Antigen (PSMA) is known to be highly expressed on the endothelial cells of the neovasculature of several solid tumors other than prostate cancer, including RCC. In this context, recent preliminary studies reported a promising role for positron emission tomography (PET)/CT with radiolabeled molecules targeting PSMA, in alternative to fluorodeoxyglucose (FDG) in RCC patients. PURPOSE: The aim of our review is to provide an updated overview of current evidences and major limitations regarding the use of PSMA PET/CT in RCC.
methodsA literature search, up to 31 December 2021, was performed using the following electronic databases: PubMed, SCOPUS, Web of Science, and Google Scholar.
resultsThe findings of this review suggest that PSMA PET/CT could represent a valid imaging option for diagnosis, staging, and therapy response evaluation in RCC, particularly in clear cell RCC.
conclusionsFurther studies are needed for this "relatively" new imaging modality to consolidate its indications, timing, and practical procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.